SCHEMBL6322730

SCHEMBL6322730

c1ccc(-c2ccccc2-c2cccc3[nH]ccc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.61
ASH1L Q9NR48 1/20 0.51
MAPK14 Q16539 4/20 0.49
AHR P35869 1/20 0.47
PIK3CB P42338 2/20 0.45
BRD4 O60885 1/20 0.45
HPGDS O60760 1/20 0.45
METAP2 P50579 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
PIK3CG P48736 1/20 0.44
CHEK1 O14757 1/20 0.44
CLK4 Q9HAZ1 2/20 0.43
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43
DAPK3 O43293 1/20 0.43
JAK2 O60674 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29712113 0.92 PIK3CD (0.70) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL2193011 0.92 PIK3CD (0.70) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL27725234 0.89 PIK3CD (0.66) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL10945814 0.88 PIK3CD (0.75) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL20540332 0.85 PIK3CD (0.64) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL6321711 0.81 ASH1L (0.60) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL28889117 0.79 PIK3CD (0.54) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL22013889 0.78 PIK3CD (0.53) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL7088143 0.78 PIK3CD (0.57) PIK3CDASH1LMAPK14AHRPIK3CB
SCHEMBL7085001 0.77 PIK3CD (0.53) PIK3CDASH1LMAPK14PIK3CBHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 PIK3CD 365/4885ASH1L 1883/4885MAPK14 535/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 PIK3CD 365/4885ASH1L 1883/4885MAPK14 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.